Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Advanced Discovery Research LLC

Neither a doctor nor a teaching hospital

Research payments

$1,378,067

228 payments

Through program year 2025, Advanced Discovery Research LLC is reported as receiving $1,378,067 in research payments, across 228 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $313,923 67
2024 Research $340,984 29
2023 Research $390,955 98
2022 Research $332,206 34

Breakdown

Who paid Research payments · program years 2022–2025
  1. Otsuka Pharmaceutical Development & Commercialization, Inc. $493,173 13 payments
  2. Sumitomo Pharma America, Inc. $376,869 114 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $338,280 7 payments
  4. Janssen Research & Development, LLC $54,228 8 payments
  5. AbbVie, Inc. $36,052 9 payments
  6. ITI, Inc. $30,298 9 payments
  7. Boehringer Ingelheim International GmbH $21,735 37 payments
  8. Boehringer Ingelheim Pharma GmbH & Co.KG $13,335 3 payments
  9. Vanda Pharmaceuticals Inc. $12,688 1 payment
  10. Sunovion Pharmaceuticals Inc. $1,410 27 payments
Studies the money was for Research payments · program years 2022–2025
  1. Phase II dose finding trial in monotherapy for MDD $218,104 6 payments
  2. A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication $212,659 45 payments
  3. A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder $170,707 1 payment
  4. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deudextromethorphan Hydrobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimers Type $109,959 4 payments
  5. A Multi-Center, Randomized, Controlled Trial to Evaluate the Effectiveness of A Digital Therapeutic (CT-152) As Adjunctive Therapy in Adult Subjects Diagnosed With Major Depressive Disorder $92,451 2 payments
  6. An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication $75,925 6 payments
  7. Proof of Concept and DRF with TRPC4/5 inhibitor in MDD $73,153 2 payments
  8. Proof of Concept and DRF with TRPC4 5 inhibitor in $64,121 3 payments
  9. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deudextromethorphan Hydrobromide [D6 Dm]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimers Type $60,933 1 payment
  10. A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso $49,732 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record